Another study revealed that sorafenib-treated HCC cells upregulate cholesterol biosynthesis via caspase-3–dependent and SREBP 2-mediated mechanisms, leading to activation of the SHH signaling pathway and drug resistance (30). This evidence concerns the gene SHH and hepatocellular carcinoma.